Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: The Swiss HIV Cohort Study

HIV Medicine

Volumn 7, Issue 6, 2006, Pages 404-410

  Glass, T R ^a   Ungsedhapand, C ^a   Wolbers, M ^a   Weber, R ^b,k   Vernazza, P L ^c   Rickenbach, M ^d,j   Furrer, H ^e,i   Bernasconi, E ^f   Cavassini, M ^d   Hirschel, B ^g   Battegay, M ^h   Bucher, Heiner C ^a   Boni J ^k   Burgisser Ph ^k   Cattacin, S ^k   Dubs, R ^k   Egger, M ^k   Elzi, L ^k   Erb, P ^k   Fantelli, K ^k   Fischer, M ^k   Flepp, M ^k   Fontana, A ^k   Francioli, P ^d   Gorgievski, M ^k   Gunthard H ^k   Kaiser, L ^k   Kind, C ^k   Klimkait, Th ^k   Ledergerber, B ^k   Lauper, U ^k   Opravil, M ^k   Paccaud, F ^k   Pantaleo, G ^k   Perrin, L ^k   Piffaretti, J C ^k   Rudin, C ^k   Schmid, P ^k   Schupbach J ^k   Speck, R ^k   Telenti, A ^k   Trkola, A ^k   Vernazza, P ^k   Yerly, S ^k   more..

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ Clinical and Laboratory Committee

^j Data Center

^k NONE

more..

Author keywords

Cardiovascular diseases; Cardiovascular risk factors; Highly active antiretroviral therapy; HIV infection; Prevalence; Time trends

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL OBSERVATION; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; ISCHEMIC HEART DISEASE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SMOKING; SWITZERLAND;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS; DYSLIPIDEMIAS; HIV INFECTIONS; HUMANS; HYPERTENSION; MIDDLE AGED; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; SWITZERLAND; TIME FACTORS;

EID: 33746442434     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2006.00400.x     Document Type: Article

References (22)

1. Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
2. Friis-Moller N, Reiss P, El Sadr W et al. Exposure to PI and NNRTI and risk of myocardial infarction from the D. A. D. Study. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [Abstract 144].
3. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-2486.
4. Currier JS, Taylor A, Boyd F et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33: 506-512.
5. Holmberg SD, Moorman AC, Williamson JM et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360: 1747-1748.
6. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30: 471-477.
7. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348: 702-710.
8. Friis-Moller N, Weber R, Reiss P et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 1179-1193.
9. Bergersen BM, Sandvik L, Bruun JN, Tonstad S. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis 2004; 23: 625-630.
10. Fontas E, van Leth F, Sabin CA et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004; 189: 1056-1074.
11. Fellay J, Boubaker K, Ledergerber B et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001; 358: 1322-1327.
12. Anonymous. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486-2497.
13. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. J Am Med Assoc 2003; 289: 2560-2572.
14. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004; 27(Suppl. 1): S15-S35.
15. Battegay E, Bertel O, Darioli R et al. Empfehlungen 1999 zur Behandlungsindikation des Risikofaktors Cholesterin. Schweiz Ärztezeitung 2000; 81: 2139-2149.
16. Green ML. Evaluation and management of dyslipidemia in patients with HIV infection. J Gen Intern Med 2002; 17: 797-810.
17. Santos J, Palacios R, Gonzalez M, Ruiz J, Marquez M. Atherogenic lipid profile and cardiovascular risk factors in HIV-infected patients (Netar Study). Int J STD AIDS 2005; 16: 677-680.
18. El Sadr W, Neaton J, Neuhaus J, Gordin F. Comparison of risk factors for coronary heart disease among men and women enrolled in the SMART Study (CPCRA 065). 10th Conference on Retrovirus and Opportunistic Infections. Boston, MA, February 2003 [Abstract 745].
19. Brindle P, Emberson J, Lampe F et al. Predictive accuracy of the Framingham coronary risk score in British men: Prospective cohort study. Br Med J 2003; 327: 1267.
20. Law M, Friis-Moller N, Weber R et al. Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med 2003; 4: 1-10.
21. Young J, Weber R, Rickenbach M et al. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther 2005; 10: 585-591.
22. Glass T, Vernazza P, Weber R et al. Predictors of successful cardiovascular risk factor management in HIV-infected patients at moderate to high 10 years risk of coronary heart disease: The Swiss HIV Cohort Study. 10th European AIDS Conference/EACS. Dublin, Ireland, November 2005 [Abstract PE9.5/8].